Join to View Full Profile
45 E 89th St11CNew York, NY 10128
Phone+1 917-727-8353
Dr. Takeshita is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988- Yale-New Haven Medical CenterResidency, Internal Medicine, 1984 - 1986
Yale School of MedicineClass of 1983
Certifications & Licensure
NY State Medical License 1994 - 2026
CT State Medical License 1986 - 1995
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 1 citationsA Case Report of Bacterial Meningitis Caused by an Emerging Strain of Penicillin-Resistant Non-Vaccine Serotype 10A.Sonoko Minato, Michiko Yoshida, Kensuke Shoji, Nobuyuki Yotani, Kenichi Takeshita
Japanese Journal of Infectious Diseases. 2021-01-29 - 38 citationsLenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myelomaShinsuke Iida, Takaaki Chou, Shinichiro Okamoto, Hirokazu Nagai, Kiyohiko Hatake
International Journal of Hematology. 2010-06-18 - 205 citationsLenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's LymphomaThomas E. Witzig, Peter H. Wiernik, Timothy E. Moore, Craig B. Reeder, Craig Cole
Journal of Clinical Oncology. 2009-11-10
Press Mentions
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine TherapyFebruary 28th, 2025- Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerJanuary 31st, 2025
- Datopotamab Deruxtecan Granted Priority Review in the U.S. For Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerJanuary 13th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
